82205-58-1

Usage

Uses

Used in Medicinal Chemistry:
1-(5-Nitropyridin-2-yl)piperazine is used as a building block for the synthesis of pharmaceutical drugs and bioactive molecules, leveraging its structural features and pharmacological properties to develop potential drug candidates for the treatment of various diseases.
Used in Chemical and Biological Research:
1-(5-Nitropyridin-2-yl)piperazine is used as a reference standard in chemical and biological research, facilitating the analysis and comparison of other compounds. Additionally, it serves as a reagent in organic synthesis, contributing to the development of new chemical entities and processes.

InChI:InChI=1/C9H12N4O2/c14-13(15)8-1-2-9(11-7-8)12-5-3-10-4-6-12/h1-2,7,10H,3-6H2/p+2

Upstream product

• 110-85-0 piperazine 
• 4487-59-6 2-bromo-5-nitropyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 193902-78-2 tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate 
• 1227862-56-7 1-(5-nitropyridin-2-yl)-4-hydroxy-4-phenylpiperidine 

Downstream Products

• 193902-78-2 tert-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate 
• 1331778-53-0 C₂₁H₂₆N₄O₄ 
• 119285-07-3 4-(5-aminopyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 1343404-04-5 (4-fluorophenyl)(4-(5-nitropyridin-2-yl)piperazin-1-yl)methanone 
• 1062298-91-2 1-(5-nitropyridin-2-yl)-4-(phenylcarbonyl)piperazine 
• 1088209-92-0 (4-methoxyphenyl)(4-(5-nitropyridin-2-yl)piperazin-1-yl)methanone 
• 1017143-28-0 6-[4-(phenylcarbonyl)piperazin-1-yl]pyridin-3-amine 
• 1017143-31-5 (4-(5-aminopyridin-2-yl)piperazin-1-yl)(cyclohexyl)methanone 
• 1017171-62-8 (4-(5-aminopyridin-2-yl)piperazin-1-yl)(4-fluorophenyl)methanone 
• 1343403-94-0 (4-(5-aminopyridin-2-yl)piperazin-1-yl)(4-methoxyphenyl)methanone 
• 1343404-03-4 cyclohexyl(4-(5-nitropyridin-2-yl)piperazin-1-yl)methanone 
• 1275991-29-1 4-(5-(3,5-dimethylbenzofuran-2-carboxamido)pyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide 
• 1275991-88-2 N-(2-fluorophenyl)-4-(5-(5-methoxy-3-methylbenzofuran-2-carboxamido)pyridin-2-yl)piperazine-1-carboxamide 
• 1275991-25-7 4-(5-(5-fluoro-3-methylbenzofuran-2-carboxamido)pyridin-2-yl)-N-(2-fluorophenyl)piperazine-1-carboxamide 

Relevant academic research and scientific papers

Novel piperazine based compounds as potential inhibitors for SARS-CoV-2 Protease Enzyme: Synthesis and molecular docking study

Structurally diverse piperazine-based compounds hybrid with thiadiazole, isatin or with sulfur/nitrogen, functionalities were synthesized. The structures of the new compounds were established based on their spectral data and elemental analysis. The physicochemical, bioactivity scores and pharmacokinetic behavior of all the prepared ligands were evaluated using in silico computational tools. The new piperazine ligands have been screened for their inhibition activity against SARS-CoV-2 protease enzyme using molecular docking analysis. The docking studies showed that all the ligands have been docked with negative dock energy onto the target protease protein. Moreover, Molecular interaction studies revealed that SARS-CoV-2 protease enzyme had strong hydrogen bonding interactions with piperazine ligands. The present in silico study thus, provided some guidance to facilitate drug design targeting the SARS-CoV-2 main protease.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said che

Dihalopropenyl ether compounds,d and preparation and application thereof

The invention discloses dihalopropenyl ether compounds, preparation and application thereof. The compound is shown in a formula (I), wherein Q, R, R1, R2, R3, R4, R5, n, and v in the formula are defined in the description. The compounds shown in the formula (I) have insecticidal and/or bactericidal biological activity, and has very high activity particularly on pests such as mythimna separata and plutella xylostella.

Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors

The structure-activity relationship studies of a novel series of carboxylic acid derivatives of pyridine-carboxamides as DGAT-1 inhibitors is described. The optimization of the initial lead compound 6 based on in vitro and in vivo activity led to the disc

SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS

Described herein are compounds of formula I. The compounds of formula I act as DGAT-1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability

To improve antifungal activities, water solubility and bioavailability, a series of novel analogues of itraconazole-containing pyridine rings were designed and synthesized. Their antifungal activities were evaluated in vitro against six clinically important fungi by measuring the minimal inhibitory concentrations (MICs). Most of the compounds showed more potent antifungal activities than that of itraconazole. In particular, the analogues 30d, 30c, 31c, and 36d exhibited much higher solubility and bioavailability than that of itraconazole. The bioavailability of 36d (42.2%) was five times higher than that of itraconazole (8%) and was negative for genetic toxicology in the Ames test.

Synthesis and solid state study of pyridine- and pyrimidine-based fragment libraries

A library of pyridines and pyrimidines has been synthesised in excellent yields employing microwave and flow chemistry methodologies. Work-up bottlenecks have been facilitated substantially by the use of supported reagents and many of the final compounds have been studied in the solid state by single crystal X-ray diffraction.

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (DGAT) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below:

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below.